Vitamin D 25-OH Test and Deficiency Thresholds

A vitamin D test result rarely means what it looks like it means. The number on the report, serum 25-hydroxyvitamin D, sounds like a clean, single data point. But the cutoffs used to judge that number don't agree with each other, and the physiology behind the test is messier than a simple pass or fail line suggests.

Why a single number from the lab report is not enough on its own, the PTH signal

The body has its own alarm system for vitamin D trouble, and it's not the 25-OH test itself. It's parathyroid hormone, or PTH.

PTH rises when calcium balance gets threatened, and vitamin D stores falling too low is one of the main triggers. PTH stays flat and steady while 25(OH)D sits above roughly 31 ng/mL. Drop below that point, though, and PTH starts climbing as the body scrambles to keep calcium levels stable, pulling it from bone if it has to.

That creates an odd situation. Someone with a 25-OH result in the low-to-mid 30s ng/mL, which most lab reports would stamp "sufficient", can still be walking around with elevated PTH. The lab slip says fine. The body's alarm system says otherwise.

Why doesn't this just get folded into a cleaner threshold, then? Because the inflection point, the level where falling vitamin D starts to trigger a PTH response, swings wildly from person to person. In adults it's been observed anywhere from 8 to 44 ng/mL. In adolescents, 11 to 43 ng/mL. That's not a narrow band, that's most of the clinically relevant range. So a PTH check doesn't hand over a better universal number, it just proves the point that no single number was ever going to work for everyone. A result that clears the lab's reference range doesn't necessarily mean the body agrees, and PTH is the second opinion to ask for when the picture doesn't quite fit.

Where the official threshold lines are drawn

None of this disagreement is sloppiness. Different institutions are answering different questions, bone health, disease prevention, population-wide guidance, and they land in different places because they're not solving for the same thing.

The Institute of Medicine (now the National Academy of Medicine) floor. Deficiency, by this framework, means below 20 ng/mL (50 nmol/L). It was built around bone health in otherwise healthy people, nothing broader. Most commercial lab reference ranges still lean on this number, so it's what shows up on the vast majority of patient results.

The old Endocrine Society target, now abandoned. For years, 30 ng/mL (75 nmol/L) was the sufficiency line clinicians reached for. That guidance has been formally walked back. A 2024 Endocrine Society clinical practice guideline dropped it, and went further: it declined to endorse any specific number for sufficiency, insufficiency, or deficiency tied to disease prevention. The same guideline also found no trial evidence to support routine population-wide screening, even in higher-risk groups like people with obesity or darker skin. (Corrections to that guideline were published in a clinical endocrinology journal in March and July of 2025, though they don't appear to shift the core recommendations.)

UK and NICE guidance, updated by a primary care body (Bedfordshire, Luton and Milton Keynes ICB) in May 2025, draws three bands: deficient below 25 nmol/L, insufficient between 25 and 50 nmol/L (treated case by case), and sufficient above 50 nmol/L, which is around 20 ng/mL. Data cited in that guidance puts roughly a fifth of adults in that country below the 25 nmol/L deficiency line. Notably, the UK approach doesn't recommend routine testing for people without symptoms, even in higher-risk groups. It leans on maintenance supplementation instead of testing everyone first.

Medscape's clinical reference range, updated in August 2026, lists total 25(OH)D as 25 to 80 ng/mL, alongside the standard clinical shorthand bands for sufficiency, insufficiency, and deficiency.

A study published in one journal in 2022, looking at 1,097 hip fracture patients, found that 27 ng/mL predicted low bone mineral density better than the traditional 30 ng/mL cutoff, using a statistical measure called the Youden index. Below 27 ng/mL, 74.7% of patients in the study had low bone density, versus 67% of those above it (p = 0.02). In a chronic kidney disease subgroup, falling below 27 ng/mL carried a mortality odds ratio of 1.61 (95% CI: 1.08 to 2.39). This is one retrospective study in one specific patient population, a hip-fracture cohort. It's a data point.

Where practicing clinicians outside the fracture-prevention world tend to land. Many clinicians focused on longevity or performance aim for 40 to 60 ng/mL, based on observational links to immune function, muscle performance, and lower all-cause mortality. An analysis by one researcher, cited in a medical news outlet, found the best outcomes clustering around 36 to 40 ng/mL across a spread of endpoints: bone density, lower-body function, falls, fractures, colorectal cancer. None of this is written into a major guideline. It's just where clinical practice has drifted, based on the data available.

Stack these up and the pattern is obvious. The IOM says 20 ng/mL covers bone health. The UK's version of "sufficient" is also near 20 ng/mL, just measured in different units. The Endocrine Society, as of 2024, won't commit to a number at all for disease prevention. And plenty of clinicians in practice are aiming twice as high. Whatever number is printed on a lab report reflects one institution's choice for one specific purpose.

Who is most likely to have a low result

Scale matters here first. A pooled analysis covering 7.9 million participants across population studies from 2000 to 2022 found 47.9% below 50 nmol/L, and 76.6% below 75 nmol/L. Roughly half the world sits under even the most conservative deficiency line.

A study tracking vitamin D levels from hospital admissions between 2017 and 2025 found deficiency rates barely moved, which should give supplement companies pause. 54.6% deficient in 2017, 55.6% in 2025, no statistically significant difference (p = 0.996). Awareness has exploded. Supplement aisles have multiplied. The actual number of deficient people hasn't budged in eight years.

Some groups carry far more of that burden than others.

Older adults show up heavily in the data, with 54.8% of adults 65 and older in Northern Britain classified as insufficient. Ethnic minority populations fare worse still, at 72.1% low or deficient, and without the seasonal swing seen in lighter-skinned populations, because melanin blocks the sunlight-driven synthesis pathway regardless of the time of year. Females made up 69.5% of deficient cases in one study population, and adolescents between 10 and 19 ranked among the most affected age groups, with a mean level as low as 21.1 ng/mL (± 11.9). People with obesity face a different mechanism entirely: vitamin D is fat-soluble, so it gets sequestered in adipose tissue and simply doesn't circulate the way it should, no matter how much gets consumed. Malabsorption conditions (coeliac disease, Crohn's, ulcerative colitis, post-bariatric surgery) block uptake at the gut level. And a long list of common medications, antiepileptics like carbamazepine and phenytoin, corticosteroids, rifampicin, colestyramine, thiazide diuretics, digoxin, calcium-channel blockers, Orlistat, actively speed up how fast the body breaks down both the storage and active forms of vitamin D, or block absorption outright.

Then there's sun exposure, or the lack of it. For a fair-skinned adult, regular midday sun exposure on uncovered skin, a few times a week, is generally enough to keep levels up. But that baseline gets missed constantly by people who work indoors, stay housebound, or cover their skin for cultural or health reasons, which loops right back to several of the high-risk groups above. Knowing the problem exists clearly hasn't been enough to close the gap.

What a low result can feel like, symptoms and the physiology behind them

Deficiency is often quiet. That's precisely the argument for testing before symptoms show up, because by the time they do, the deficiency has usually been sitting there for a while.

When symptoms do appear, they tend to show up as persistent fatigue, bone or back pain, muscle weakness or cramping, frequent infections, a low mood, thinning hair, or wounds that heal slower than expected.

The fatigue piece has a mechanism behind it. Research in adults with vitamin D deficiency has linked correcting the deficiency to improvements in muscle function and fatigue symptoms, pointing to effects on the cellular machinery that produces energy. That's part of why clinicians are advised to consider checking vitamin D levels in patients with unexplained fatigue or nonspecific muscle and joint pain, particularly when risk factors are present. Not as a blanket screen for everyone without symptoms, but as a reasonable next step when the clinical picture fits.

Severe, sustained deficiency sets off a more serious chain of events. Low calcium (hypocalcemia) triggers secondary hyperparathyroidism, and the body starts pulling calcium out of bone to compensate. Left uncorrected, that becomes accelerated bone demineralization, osteomalacia in adults (bones that go soft and painful), rickets in children, and a higher risk of fracture. The muscle weakness and fatigue that occur in this context aren't vague complaints, they reflect real disruption to calcium-dependent signaling in muscle tissue.

The UK's May 2025 guidance is specific about when testing actually makes sense: suspected osteomalacia, chronic widespread pain paired with weakness close to the trunk (proximal muscle weakness), signs of hypocalcemia like cramping, numbness, tingling, or spasm, or before starting any bone-active medication.

Symptoms map onto physiology fairly cleanly at this point. What gets murkier is what low vitamin D means for disease risk outside the bones, and that's where the evidence gets both interesting and genuinely contested.

What low vitamin D is associated with beyond bone

The Endocrine Society's 2024 guideline links low 25(OH)D to a wide range of conditions, musculoskeletal, metabolic, cardiovascular, cancer, autoimmune, infectious, and those associations are well documented. A causal link for most of them isn't.

Cardiovascular disease is a good example of that gap. Observational studies consistently find higher rates of cardiovascular disease in people with low 25(OH)D. But intervention trial evidence has not consistently shown that supplementation reduces cardiovascular-specific illness or death, even where broader mortality signals have appeared. The association holds up. Proof that fixing the number fixes the heart risk doesn't, at least not yet.

TARGET-D is a cardiac secondary prevention study with results presented at the American Heart Association's Scientific Sessions in 2025. It enrolled 630 people, average age 63, all within a month of having a heart attack. At enrollment, 87% had low vitamin D, averaging 27 ng/mL. The trial used tailored vitamin D3 dosing to push people toward a target above 40 ng/mL, aiming for a range of 40 to 80 ng/mL. As of November 2025, these results hadn't been peer-reviewed. Promising, but not yet settled science.

On the metabolic side, deficiency has been linked to impaired insulin secretion, insulin resistance, poor glucose tolerance, and elevated insulin levels (hyperinsulinemia). Obesity complicates this further and cuts in both directions: excess fat tissue sequesters vitamin D and lowers circulating levels, while low vitamin D itself is associated with worse metabolic markers, making it genuinely hard to untangle which factor is driving which outcome, or whether they're feeding each other in a loop.

That tangled relationship, cause versus consequence versus shared risk factor, is more or less the throughline for vitamin D research outside the skeleton. The associations are consistent enough to take seriously. Whether correcting a number on a lab report actually changes those downstream outcomes is a different question, and for most of them, it's one the evidence hasn't answered yet.